These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 33230696)

  • 1. The usefulness of Olanzapine plasma concentrations in monitoring treatment efficacy and metabolic disturbances in first-episode psychosis.
    Arnaiz JA; Rodrigues-Silva C; Mezquida G; Amoretti S; Cuesta MJ; Fraguas D; Lobo A; González-Pinto A; Díaz-Caneja MC; Corripio I; Vieta E; Baeza I; Mané A; García-Rizo C; Bioque M; Saiz J; Bernardo M; Mas S;
    Psychopharmacology (Berl); 2021 Mar; 238(3):665-676. PubMed ID: 33230696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone.
    Perez-Iglesias R; Crespo-Facorro B; Amado JA; Garcia-Unzueta MT; Ramirez-Bonilla ML; Gonzalez-Blanch C; Martinez-Garcia O; Vazquez-Barquero JL
    J Clin Psychiatry; 2007 Nov; 68(11):1733-40. PubMed ID: 18052567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Pilot Study of the Usefulness of a Single Olanzapine Plasma Concentration as an Indicator of Early Drug Effect in a Small Sample of First-Episode Psychosis Patients.
    Zabala A; Bustillo M; Querejeta I; Alonso M; Mentxaka O; González-Pinto A; Ugarte A; Meana JJ; Gutiérrez M; Segarra R
    J Clin Psychopharmacol; 2017 Oct; 37(5):569-577. PubMed ID: 28796022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Retrospective Analysis of Steady-State Olanzapine Concentrations in Chinese Patients Using Therapeutic Drug Monitoring: Effects of Valproate and Other Factors.
    Deng SH; Wang ZZ; Lu HY; Li L; Hu JQ; Zhu XQ; Xie HS; Chen HZ; Zhang M; Ni XJ; Qiu C; Shang DW; Wen YG
    Ther Drug Monit; 2020 Aug; 42(4):636-642. PubMed ID: 32039940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of Valproic Acid on Olanzapine Serum Concentration: A Study Including 2791 Patients Treated With Olanzapine Tablets or Long-Acting Injections.
    Tveito M; Smith RL; Høiseth G; Molden E
    J Clin Psychopharmacol; 2019; 39(6):561-566. PubMed ID: 31688390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.
    Kinon BJ; Basson BR; Gilmore JA; Tollefson GD
    J Clin Psychiatry; 2001 Feb; 62(2):92-100. PubMed ID: 11247108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses.
    Melkersson KI; Hulting AL; Brismar KE
    J Clin Psychiatry; 2000 Oct; 61(10):742-9. PubMed ID: 11078035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapine.
    Kryzhanovskaya LA; Xu W; Millen BA; Acharya N; Jen KY; Osuntokun O
    J Child Adolesc Psychopharmacol; 2012 Apr; 22(2):157-65. PubMed ID: 22372514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients.
    Bergemann N; Frick A; Parzer P; Kopitz J
    Pharmacopsychiatry; 2004 Mar; 37(2):63-8. PubMed ID: 15048613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic Drug Monitoring in Children and Adolescents Under Pharmacotherapy With Olanzapine in Daily Clinical Practice.
    Fekete S; Wewetzer C; Mehler-Wex C; Holtkamp K; Burger R; Reichert S; Taurines R; Romanos M; Gerlach M; Egberts K
    Ther Drug Monit; 2017 Jun; 39(3):273-281. PubMed ID: 28383317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial.
    Johnsen E; Kroken RA; Løberg EM; Rettenbacher M; Joa I; Larsen TK; Reitan SK; Walla B; Alisauskiene R; Anda LG; Bartz-Johannessen C; Berle JØ; Bjarke J; Fathian F; Hugdahl K; Kjelby E; Sinkeviciute I; Skrede S; Stabell L; Steen VM; Fleischhacker WW
    Lancet Psychiatry; 2020 Nov; 7(11):945-954. PubMed ID: 33069317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors.
    Pérez-Iglesias R; Martínez-García O; Pardo-Garcia G; Amado JA; Garcia-Unzueta MT; Tabares-Seisdedos R; Crespo-Facorro B
    Int J Neuropsychopharmacol; 2014 Jan; 17(1):41-51. PubMed ID: 24103107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antipsychotic treatment in child and adolescent first-episode psychosis: a longitudinal naturalistic approach.
    Castro-Fornieles J; Parellada M; Soutullo CA; Baeza I; Gonzalez-Pinto A; Graell M; Paya B; Moreno D; de la Serna E; Arango C
    J Child Adolesc Psychopharmacol; 2008 Aug; 18(4):327-36. PubMed ID: 18759642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.
    Crespo-Facorro B; Pérez-Iglesias R; Ramirez-Bonilla M; Martínez-García O; Llorca J; Luis Vázquez-Barquero J
    J Clin Psychiatry; 2006 Oct; 67(10):1511-21. PubMed ID: 17107241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral glucose tolerance test performance in olanzapine-treated schizophrenia-spectrum patients is predicted by BMI and triglycerides but not olanzapine dose or duration.
    Guina J; Roy S; Gupta A; Langleben DD; Elman I
    Hum Psychopharmacol; 2017 Jul; 32(4):. PubMed ID: 28573760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis.
    Graham KA; Perkins DO; Edwards LJ; Barrier RC; Lieberman JA; Harp JB
    Am J Psychiatry; 2005 Jan; 162(1):118-23. PubMed ID: 15625209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial.
    Narula PK; Rehan HS; Unni KE; Gupta N
    Schizophr Res; 2010 May; 118(1-3):218-23. PubMed ID: 20207521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of valproate on olanzapine plasma concentrations in patients with bipolar or schizoaffective disorder.
    Spina E; D'Arrigo C; Santoro V; Muscatello MR; Pandolfo G; Zoccali R; Diaz FJ; de Leon J
    Ther Drug Monit; 2009 Dec; 31(6):758-63. PubMed ID: 19865002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Objective and subjective efficacy as well as tolerability of olanzapine in the acute treatment of 120 patients with schizophrenia spectrum disorders.
    Lambert M; Holzbach R; Moritz S; Postel N; Krausz M; Naber D
    Int Clin Psychopharmacol; 2003 Sep; 18(5):251-60. PubMed ID: 12920385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic effects associated with atypical antipsychotic treatment in the developmentally disabled.
    McKee JR; Bodfish JW; Mahorney SL; Heeth WL; Ball MP
    J Clin Psychiatry; 2005 Sep; 66(9):1161-8. PubMed ID: 16187775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.